Compare DGII & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | DNLI |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 1995 | 2017 |
| Metric | DGII | DNLI |
|---|---|---|
| Price | $75.31 | $18.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $85.40 | $35.75 |
| AVG Volume (30 Days) | 320.6K | ★ 1.7M |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.05 | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $430,221,000.00 | N/A |
| Revenue This Year | $23.69 | N/A |
| Revenue Next Year | $8.72 | $158.26 |
| P/E Ratio | $72.92 | ★ N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $34.41 | $13.75 |
| 52 Week High | $86.84 | $27.30 |
| Indicator | DGII | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 40.38 |
| Support Level | $71.22 | $18.07 |
| Resistance Level | $77.44 | $20.84 |
| Average True Range (ATR) | 2.61 | 0.81 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 85.12 | 43.07 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.